Quick Links

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Clovis Oncology, and Tesaro Inc.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Medical Crossfire®: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation

ASCO: Medical Crossfire®: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation

Sunday, June 3, 2018
Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
International Ballroom North (Lobby Level)
720 S. Michigan Avenue
Chicago, IL 60605


The landscape of therapeutic options for patients with ovarian cancer is evolving at a rapid pace. Multiple poly (ADP-ribose) polymerase (PARP) inhibitors have been approved for both treatment and ongoing maintenance indications following the results of recent key studies. These approvals have heralded an opportunity to significantly improve outcomes for patients with ovarian cancer. Other exciting trials in ovarian cancer are exploring the use of PARP inhibitors in combination with different agents. The accelerated pace and volume of clinical advancements associated with PARP inhibition has presented a challenge for clinicians to stay current and arm themselves with the clinical knowledge and insight necessary to optimize safety and efficacy outcomes.

To help clinicians meet this challenge, this symposium will feature a panel of experts in the management of ovarian cancer who will present and assess the latest data on PARP inhibition and the clinical implications of the data for contemporary practice. The Medical Crossfire® format for this symposium is ideally suited to facilitate clinician exchanges on key learning points pertaining to the use of PARP inhibition in ovarian cancer. During this case-based activity, clinical scenarios will be presented that explore nuances of patient care along the disease continuum. Decisions that are made in real-world clinical scenarios are not always clearly demarcated by clinical trial data, and this activity will facilitate faculty debate to substantiate diagnostic and treatment decisions when multiple options may be viable.

Clinicians participating in this activity will have the opportunity to reflect on how experts in the field of ovarian cancer management leverage key data sets to support decision making on initiation of germline and somatic testing, incorporation of homologous recombination deficiency assessment, initiation of treatment, and maintenance therapy decisions. Importantly, consideration and attention to best practices for adverse event management will be broached throughout the program. Lastly, future directions in the field will be addressed and considered in the context of how recent data readouts and highly anticipated trials may shape care for patients with ovarian cancer.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Clovis Oncology, and Tesaro Inc.

Target Audience

This educational program is intended for medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of ovarian cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the management of patients with ovarian cancer are also invited to participate.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Define safety and efficacy outcomes from clinical trials of PARP inhibitors, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy
  • Identify strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer
  • Describe the therapeutic rationale for the use of PARP inhibitors in combination with other novel treatments, evaluating specific clinical trials using PARP inhibitors in combination and recognizing the potential for enrolling patients in these trials
  • Utilize the most up-to-date clinical evidence in PARP for clinical decision-making in patients with ovarian cancer in the context of current evolving treatment options

Program Chair

Robert L. Coleman, MD, FACOG, FACS
Professor and Executive Director, Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Become a Member

Forgot Password?
Filter By